Johnson & Johnson（JNJ）株式概要
ジョンソン・エンド・ジョンソンは、その子会社とともに、ヘルスケア分野における様々な製品の研究開発、製造、販売を世界中で行っている。 詳細
JNJ Community Fair Values
Create NarrativeSee what 758 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Johnson & Johnson 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$229.32 |
| 52週高値 | US$251.71 |
| 52週安値 | US$149.04 |
| ベータ | 0.26 |
| 1ヶ月の変化 | -0.59% |
| 3ヶ月変化 | -7.12% |
| 1年変化 | 49.71% |
| 3年間の変化 | 46.38% |
| 5年間の変化 | 35.64% |
| IPOからの変化 | 36,591.26% |
最新ニュース
Recent updates
ナラティブの更新 • May 14
JNJ: Future Drug Cycle And Legal Outcomes Are Expected To Shape Returns
Analysts have nudged their average price target on Johnson & Johnson slightly higher to about $253, citing stronger momentum from new drugs like Icotyde and Inlexzo, along with increased confidence in the pipeline highlighted in recent research updates. Analyst Commentary Recent research on Johnson & Johnson clusters around the same core themes you are seeing in price target moves, with most commentary tied to execution on new products, confidence in the pipeline, and how the company is positioned within healthcare more broadly.ナラティブの更新 • Apr 24
JNJ: Fair Outlook Balances Healthcare Demand With Legal And Portfolio Reshaping Risks
The analyst price target for Johnson & Johnson has been raised by about $11 to $252.42. Analysts point to stronger modeled revenue growth, higher projected profit margins, and a slightly richer future P/E multiple as key drivers of the update.Seeking Alpha • Apr 17
Johnson & Johnson: Why I See Downside Ahead
Summary Johnson & Johnson only slightly raised its 2026 financial guidance. So JNJ expects its operational sales to be between $99.7 billion and $100.7 billion, up from $99.5 billion to $100.5 billion. In my view, this is due to the sharp decline in demand for Stelara, JNJ's former "cash cow" in the immunology franchise. Moreover, JNJ's acquisition of Intra-Cellular Therapies for $14.6 billion doesn't meet my expectations, as Caplyta sales grew by only 8.4% quarter-on-quarter to $270 million. Further in this article, you'll learn about additional reasons why I believe Johnson &Johnson's risk/reward profile is still unattractive. Read the full article on Seeking Alphaナラティブの更新 • Apr 09
JNJ: Fair Outlook Sees Healthcare Demand And Legal Outcomes Shape Resilience
Analysts have made a modest upward adjustment to the fair value estimate for Johnson & Johnson, supported by a series of recent price target increases that reflect their updated views on the product pipeline, medical technology trends, and the broader appeal of healthcare stocks. Analyst Commentary Recent research updates on Johnson & Johnson show a cluster of higher price targets and fresh coverage that investors are watching closely.
新しいナラティブ • Mar 30
Johnson & Johnson (JNJ): The $100 Billion Revenue Frontier and the MedTech Evolution
Johnson & Johnson (JNJ) is currently trading at $242.83 USD on the NYSE as of the afternoon session on March 30, 2026, reflecting a steady 1% gain for the day. After a transformative 2025 that saw the full integration of its "pure-play" healthcare strategy following the Kenvue spin-off, the company has entered 2026 with significant momentum.ナラティブの更新 • Mar 25
JNJ: Fair Outlook Balances Legal Overhang With Core Healthcare Resilience
Analysts lifted the Johnson & Johnson fair value estimate by about $3.79 to $241.08, citing higher assumed revenue growth, slightly adjusted profit margin expectations, and a modestly higher future P/E multiple supported by recent upward price target revisions across the Street. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more constructive, with a series of higher price targets clustered above the latest fair value estimate.
新しいナラティブ • Mar 18
Oncology Reliance And MedTech Execution Will Threaten Long Term Earnings Stability
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company focused on pharmaceuticals and medical technology across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Mar 11
JNJ: Pharma Pipeline Momentum Balanced By Talc And Orthopedics Uncertainty
Analysts have nudged their average price target on Johnson & Johnson higher by about $5 per share, reflecting updated views on the company’s pharmaceutical pipeline, including stronger expectations around Tremfya and other near term therapies such as Tecvayli, Inlexzo and Darzalex treatment duration. Analyst Commentary Recent Street research on Johnson & Johnson has centered on how the pharma pipeline feeds into valuation, with analysts updating targets around specific products rather than broad macro calls.ナラティブの更新 • Feb 25
JNJ: Oncology Pipeline Sale Plans And Talc Cases Will Shape Future Risk
The analyst price target for Johnson & Johnson has been raised by $1 to $232.50, as analysts factor in slightly higher revenue growth expectations, a modest adjustment to profit margin assumptions, and an updated future P/E of 25.94 following a series of recent target increases and an upgrade from major firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned positive, with several firms lifting price targets and one issuing an upgrade, while a smaller group of voices remains more cautious on how much upside is already reflected in the valuation.ナラティブの更新 • Feb 10
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Risk Balance
Analysts have lifted their Johnson & Johnson fair value estimate by about US$7 to roughly US$231, reflecting research that points to slightly higher assumed revenue growth, modestly stronger profit margins, and a marginally higher future P/E multiple following a series of recent price target increases and an upgrade from several firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more positive, with several firms adjusting price targets higher and one new initiation that frames the shares as a preferred large cap pharmaceutical name.ナラティブの更新 • Jan 27
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Balanced Risk Reward
Analysts have raised their Johnson & Johnson fair value estimate by about US$13 to roughly US$224. This reflects slightly higher modeled revenue growth, a marginally higher future P/E, and supportive Street research that includes multiple recent price target increases from major firms across the sector.
新しいナラティブ • Jan 25
Broad MedTech And Complex Therapy Platforms Will Define A Stronger Future Trajectory
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company that develops and sells pharmaceuticals and medical devices across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Jan 09
JNJ: Ortho Separation And Talc Risks Will Shape Balanced Forward Risk Reward
Analysts have nudged their fair value estimate for Johnson & Johnson slightly higher to about US$211 per share, reflecting updated views on revenue growth, profitability, and future P/E assumptions informed by recent price target increases and supportive research commentary on the company's pipeline and planned ortho separation. Analyst Commentary Recent Street research on Johnson & Johnson points to a mix of optimism around the pipeline, margin profile, and planned ortho separation, alongside ongoing attention to litigation and product risk.ナラティブの更新 • Dec 19
JNJ Future Portfolio Separation And Litigation Resolution Will Shape Balanced Risk Reward Outlook
Analysts have raised their average price target on Johnson & Johnson by about $7 to roughly $209, reflecting slightly faster expected revenue growth, a modestly higher future earnings multiple, and confidence that portfolio reshaping and pipeline execution can offset near term margin pressure. Analyst Commentary Street research on Johnson & Johnson has turned incrementally more constructive, with multiple firms lifting price targets in response to stronger fundamentals and portfolio actions that are viewed as supportive of a faster growth profile.ナラティブの更新 • Dec 05
JNJ: Future Reorganization And Litigation Outcomes Will Shape Risk Reward Balance
The analyst price target for Johnson & Johnson has been nudged higher, with fair value rising from approximately $200.82 to $202.54 per share, as analysts highlight slightly stronger long term revenue growth, modestly higher profit margins, and a richer future P/E multiple supported by an improving innovation pipeline and portfolio reshaping efforts. Analyst Commentary Recent research updates reflect a broadly constructive stance on Johnson & Johnson, with a growing number of firms highlighting improving fundamentals, a stronger growth profile, and a more compelling risk reward setup following the latest results and guidance.ナラティブの更新 • Nov 21
JNJ: Upcoming Business Reorganization and Legal Risks Will Influence Future Performance
Johnson & Johnson's analyst price target has increased slightly from $199.56 to $200.82, as analysts cite stronger-than-expected sector performance and a constructive long-term industry outlook, which support the adjustment. Analyst Commentary Recent analyst commentary on Johnson & Johnson highlights a variety of perspectives related to the company's valuation, strategic direction, and future growth potential.ナラティブの更新 • Nov 05
JNJ: Upcoming Portfolio Shifts and Legal Uncertainties Will Shape Risk-Reward Balance
Johnson & Johnson's fair value estimate has increased by $1.52 to $199.56, as analysts point to improving core growth metrics, recent strong quarterly results, and expectations for higher margins following portfolio changes. Analyst Commentary Recent Street research reveals a mix of optimism and caution among analysts following Johnson & Johnson’s latest results, portfolio changes, and evolving sector dynamics.ナラティブの更新 • Oct 22
Analyst Commentary Drives Higher Valuation Targets for Johnson & Johnson Amid Positive Company Developments
Analysts have raised their fair value price target for Johnson & Johnson from approximately $185.13 to $198.03. They cite robust quarterly results, upcoming product launches, and anticipated growth and margin improvements from the company's business transformation initiatives as key reasons for the adjustment.株主還元
| JNJ | US Pharmaceuticals | US 市場 | |
|---|---|---|---|
| 7D | -0.5% | -0.1% | -0.3% |
| 1Y | 49.7% | 38.7% | 26.7% |
業界別リターン: JNJ過去 1 年間で38.7 % の収益を上げたUS Pharmaceuticals業界を上回りました。
リターン対市場: JNJ過去 1 年間で26.7 % の収益を上げたUS市場を上回りました。
価格変動
| JNJ volatility | |
|---|---|
| JNJ Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: JNJ 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: JNJの 週次ボラティリティ ( 2% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1886 | 138,200 | Joaquin Duato | www.jnj.com |
ジョンソン・エンド・ジョンソンは、その子会社とともに、ヘルスケア分野における様々な製品の研究開発、製造、販売を世界中で行っている。革新的医療事業とメドテック事業の2つのセグメントで事業を展開している。革新的医療事業では、がん、免疫、神経科学、肺高血圧、感染症、循環器、代謝など様々な治療分野向けの製品を、小売店、卸売業者、販売業者、病院、医療従事者を通じて処方箋使用で販売している。メドテック部門は、外科、整形外科、循環器、視力分野で使用される製品ポートフォリオを卸売業者、病院、小売業者を通じて販売し、専門家分野では医師、看護師、病院、眼科専門家、クリニックで使用されている。また、関節再建、外傷、脊椎、スポーツ関連傷害などをサポートする製品や実現技術、開腹手術、腹腔鏡手術、ロボット手術、器具、エネルギー機器、ステープリングシステム、創傷閉鎖、バイオサージェリー製品、デジタルおよびロボット技術、乳房の美容と再建、ACUVUEブランドのコンタクトレンズ、白内障手術用眼内レンズ、TECNISブランドの白内障および屈折矯正手術に使用されるその他の製品も提供している。同社は1886年に設立され、ニュージャージー州ニューブランズウィックに本社を置いている。
Johnson & Johnson 基礎のまとめ
| JNJ 基礎統計学 | |
|---|---|
| 時価総額 | US$553.66b |
| 収益（TTM） | US$21.04b |
| 売上高(TTM) | US$96.36b |
26.2x
PER（株価収益率5.7x
P/SレシオJNJ は割高か？
公正価値と評価分析を参照収益と収入
| JNJ 損益計算書（TTM） | |
|---|---|
| 収益 | US$96.36b |
| 売上原価 | US$30.80b |
| 売上総利益 | US$65.56b |
| その他の費用 | US$44.52b |
| 収益 | US$21.04b |
直近の収益報告
Mar 29, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 8.74 |
| グロス・マージン | 68.04% |
| 純利益率 | 21.83% |
| 有利子負債／自己資本比率 | 67.7% |
JNJ の長期的なパフォーマンスは？
過去の実績と比較を見る| Johnson & Johnson 配当日 | |
|---|---|
| 配当落ち日 | May 26 2026 |
| 配当支払日 | Jun 09 2026 |
| 配当落ちまでの日数 | 5 days |
| 配当支払日までの日数 | 19 days |
JNJ 配当は確実ですか？
JNJ 配当履歴とベンチマークを見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/20 07:56 |
| 終値 | 2026/05/20 00:00 |
| 収益 | 2026/03/29 |
| 年間収益 | 2025/12/28 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Johnson & Johnson 23 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。53
| アナリスト | 機関 |
|---|---|
| David Toung | Argus Research Company |
| Matthew Miksic | Barclays |
| Lee Hambright | Bernstein |